西酞普兰联合养血清脑颗粒治疗脑卒中后抑郁的临床观察

目的:观察西酞普兰联合养血清脑颗粒治疗脑卒中后抑郁的疗效和安全性。方法:选取120例确诊为脑卒中后抑郁的患者,按照随机数字表法均分为4组。对照组患者采用常规治疗;观察一组患者在对照组治疗基础上加服西酞普兰;观察二组患者在对照组治疗基础上加服养血清脑颗粒;观察三组在对照组治疗基础上加服西酞普兰和养血清脑颗粒。4组患者疗程均为6周。观察治疗前和治疗2、4、6周后患者的汉密尔顿抑郁量表(HAMD)和副反应量表(TESS)评分,评定疗效和安全性。结果:治疗6周后,观察一组、观察二组、观察三组的总有效率分别为86.7%、83.3%、93.3%,对照组为56.7%,观察三组最高,对照组最低,分别与其他3组比较差异均有统计学意义(P<0.05),而观察一组与观察二组差异无统计学意义(P>0.05)。治疗前4组HAMD评分比较差异无统计学意义(P>0.05);观察一组、观察二组、观察三组治疗2、4、6周后HAMD评分均较治疗前显著降低,且治疗6周后观察三组的HAMD评分最低,与其他组比较差异有统计学意义(P<0.05)。4组的不良反应症状均较轻,发生率比较差异无统计学意义(P>0.05)。结论:西酞普兰联合养血清脑颗粒治疗脑卒中后抑郁的疗效显著,且安全性较高。

Clinical Observation of Citalopram Combined with Yangxue Qingnao Particle in the Treatment of Poststroke Depression

OBJECTIVE： To observe the therapeutic efficacy and safety of citalopram combined with Yangxue qingnao particle in the treatment of post-stroke depression. METHODS： 120 patients diagnosed as post-stroke depression in our hospital were randomly divided into 4 groups with 30 cases in each group. Control group received conventional treatment; observation group 1 was additionally given citalopram, observation group 2 Yangxue qingnao particles orally and observation group 3 citalopram and Yangxue qingnao particles on the basis of control group. Treatment course lasted for 6 weeks. Before treatment and 2, 4 and 6 weeks after treatment, Hamilton Depression Scale （HAMD） and TESS were observed to evaluate therapeutic efficacy and safety. RESULTS： Total effective rates of observation group 1, 2 and 3 were 86.7%, 83.3% and 93.3% 6 weeks after treatment, respectively; while that of control group was 56.7%; that of observation group 3 was the highest, and that of control group was the lowest and there was statistical significance between control group and other 3 groups （P〈0.05）; there was no statistical significance between observation group 1 and 2 （P〉0.05）. There was no statistical significance in HAMD score among 4 groups before treatment （P〉0.05）; HAMD score of observation group 1,2 and 3 decreased significantly after 2,4 and 6 weeks of treatment; that ofobservation group 3 was the lowest after 6 weeks of treatment; there was statistical significance （P〈0.05）. Side effects of 4 groups were mild, and there was no statistical significance in the incidence （P〉0.05）. CONCLUSIONS： Citalopram combined with Yangxue qingnao particle can improve post-stroke depression significantly with high safety.